{
  "docId": "019de071-dcb4-71ce-82aa-3fde96763369",
  "docSlug": "c85401f3daf1ffc5cb0e20a3335252d7",
  "documentTitle": "BenevolentAI | SPAC Presentation Deck | 42 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 42,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a split-layout: left side defines the disease burden and market size, right side defines the mechanism of action for the drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-dcb4-71ce-82aa-3fde96763369/22",
  "deckHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369",
  "deckJsonHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369.json",
  "deckAnchorHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.5,
        "y": 0.12
      },
      "kind": "callout",
      "text": "BEN-2293: A potent PanTrk antagonist developed to relieve inflammation and provide rapid itch resolution in patients with AD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17e10218-c20f-4a4f-8bd4-8a5cdb59ce85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Atopic dermatitis is the most common chronic inflammatory skin disease... Affects 10-20% of children and up to 3% of adults... Approximately 60-70% of all cases present with mild-moderate disease severity... Prevalence is rising, with market value in 7MM forecast to exceed $14 billion by expected launch of BEN-2293 in 2028",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "487a5ae3-8f7c-4ebc-b1b2-b2dcecb4f67f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.44,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "BEN-2293 is a PanTrk inhibitor targeting TrkA,B and C receptors... BEN-2293 is expected to treat atopic dermatitis by: Inhibiting itch signaling and blocking nerve sensitization... BEN-2293 will target Mild, Moderate and Severe Atopic Dermatitis patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6801a53-86d3-42ad-bf0a-db95ad307421",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: (1) GlobalData — Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027; Evaluate Pharma - Eczema/Dermatitis : Worldwide Sales 2026 (2) GlobalData — Atopic Dermatitis: Epidemiology Forecast to 2027",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbc51adb-5947-4c12-ae7a-a2dda95e030f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Atopic Dermatitis (AD)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20e01899-c4f4-4460-84de-a702957dbc2b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "4cc89d31-2d7f-4624-a0fe-d8c5479d2631",
      "evidence": "list/bullet: Atopic dermatitis is the most common chronic inflammatory skin disease... Affects 10-20% of children and up to 3% of adults... Approximately 60-70% of all cases present with mild-moderate disease severity...",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 21,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1f7e984e-ea28-4a79-851c-c2fb54c3288f",
      "evidence": "The deck presents BenevolentAI's portfolio and progress",
      "position": 1,
      "objective": "Showcase quick wins and big bets in BenevolentAI's portfolio",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}